NASDAQ:YMAB

Y-mAbs Therapeutics (YMAB) Stock Forecast, Price & News

$5.22

+0.13 (+2.55%)

(As of 09/22/2023 06:55 PM ET)

Compare

Today's Range: $5.07
▼
$5.26
50-Day Range: $4.86
▼
$7.23
52-Week Range: $2.70
▼
$15.89

Volume: 116,600 shs
Average Volume: 420,561 shs
Market Capitalization: $227.70 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $12.63

Y-mAbs Therapeutics MarketRank™ Forecast

Analyst Rating: Hold
2.18 Rating Score
Upside/Downside: 141.9% Upside
$12.63 Price Target
Short Interest: Bearish
7.90% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.91
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.64) to ($0.51) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.97 out of 5 stars

Medical Sector

604th out of 963 stocks

Pharmaceutical Preparations Industry

281st out of 459 stocks

3.1

Analyst's Opinion

Consensus Rating
Y-mAbs Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.18, and is based on 4 buy ratings, 5 hold ratings, and 2 sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $12.63, Y-mAbs Therapeutics has a forecasted upside of 141.9% from its current price of $5.22.
Amount of Analyst Coverage
Y-mAbs Therapeutics has only been the subject of 4 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
7.90% of the float of Y-mAbs Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Y-mAbs Therapeutics has a short interest ratio ("days to cover") of 11.9, which indicates bearish sentiment.
Change versus previous month
Short interest in Y-mAbs Therapeutics has recently decreased by 17.20%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Y-mAbs Therapeutics does not currently pay a dividend.
Dividend Growth
Y-mAbs Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for YMAB.

2.7

News and Social Media Coverage

News Sentiment
Y-mAbs Therapeutics has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Y-mAbs Therapeutics this week, compared to 3 articles on an average week.
Search Interest
2 people have searched for YMAB on MarketBeat in the last 30 days.
MarketBeat Follows
Only 1 people have added Y-mAbs Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Y-mAbs Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
21.50% of the stock of Y-mAbs Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
45.45% of the stock of Y-mAbs Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Y-mAbs Therapeutics are expected to grow in the coming year, from ($0.64) to ($0.51) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Y-mAbs Therapeutics is -5.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Y-mAbs Therapeutics is -5.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Y-mAbs Therapeutics has a P/B Ratio of 2.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Y-mAbs Therapeutics (NASDAQ:YMAB) Stock

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody which has completed pivotal phase 2 clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, and Omburtamab 03-133 that is in phase 1 clinical trials for the treatment of intrathecal immunotherapy for CNS/leptomeningeal metastases. In addition, its product pipeline includes huB7-H3 for the treatment of systemic solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

YMAB Price History

30 days | 90 days | 365 days | Advanced Chart

YMAB Stock News Headlines

September 23, 2023 | americanbankingnews.com

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Average Rating of "Hold" from Analysts

September 21, 2023 | finance.yahoo.com

Y-mAbs Announces Data to be Presented at the 55th Congress of the International Society of Pediatric Oncology

September 25, 2023 | Wall Street Fundamentals (Ad)

Would Buffett Approve of This Growth Strategy?

Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.

September 6, 2023 | finance.yahoo.com

Y-mAbs to Participate at Upcoming Investor Conferences in September

August 23, 2023 | finance.yahoo.com

Wall Street Analysts Think Y-mAbs Therapeutics, Inc. (YMAB) Could Surge 88.55%: Read This Before Placing a Bet

August 23, 2023 | msn.com

JP Morgan Maintains Y-Mabs Therapeutics (YMAB) Underweight Recommendation

August 14, 2023 | msn.com

HC Wainwright & Co. Reiterates Y-Mabs Therapeutics (YMAB) Buy Recommendation

August 14, 2023 | markets.businessinsider.com

4 Analysts Have This to Say About Y-mAbs Therapeutics

September 25, 2023 | Wall Street Fundamentals (Ad)

Would Buffett Approve of This Growth Strategy?

August 13, 2023 | finance.yahoo.com

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q2 2023 Earnings Call Transcript

August 11, 2023 | investing.com

Y mAbs Therapeutics (YMAB) Earnings Dates & Reports

August 10, 2023 | finance.yahoo.com

Y-mAbs Reports Second Quarter 2023 Financial Results and Recent Corporate Developments

August 10, 2023 | finance.yahoo.com

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates

August 9, 2023 | markets.businessinsider.com

Y-mAbs Therapeutics earnings: here's what Wall Street expects

August 3, 2023 | finance.yahoo.com

Y-mAbs to Participate at Upcoming Investor Conferences

August 1, 2023 | finance.yahoo.com

Y-mAbs to Announce Second Quarter 2023 Financial and Operating Results on August 10, 2023

July 26, 2023 | msn.com

Canaccord Genuity Maintains Y-Mabs Therapeutics (YMAB) Buy Recommendation

July 26, 2023 | finance.yahoo.com

Institutional owners may take dramatic actions as Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) recent 13% drop adds to one-year losses

July 25, 2023 | markets.businessinsider.com

Analyst Expectations for Y-mAbs Therapeutics's Future

July 25, 2023 | msn.com

Y-mAbs Therapeutics: Interesting History But Questions Abound

June 8, 2023 | msn.com

Canaccord Genuity Reiterates Y-Mabs Therapeutics (YMAB) Buy Recommendation

June 7, 2023 | markets.businessinsider.com

Canaccord Genuity Sticks to Their Buy Rating for Y-Mabs Therapeutics (YMAB)

June 2, 2023 | finance.yahoo.com

Y-mAbs Therapeutics (NASDAQ:YMAB investor three-year losses grow to 81% as the stock sheds US$53m this past week

May 26, 2023 | finance.yahoo.com

Y-mAbs Announces Presentation of GD2-SADA Study at ASCO

May 26, 2023 | finance.yahoo.com

Y-mAbs Announces Presentation of Naxitamab Data at ASCO

May 23, 2023 | finance.yahoo.com

Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma approved in Brazil

May 15, 2023 | msn.com

B of A Securities Maintains Y-Mabs Therapeutics (YMAB) Neutral Recommendation

See More Headlines

Receive YMAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Y-mAbs Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

YMAB Company Calendar

Last Earnings: 8/10/2023
Today: 9/25/2023
Next Earnings (Estimated): 11/06/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:YMAB
CUSIP: N/A
CIK: 1722964
Web: www.ymabs.com
Phone: (646) 885-8505
Fax: N/A
Employees: 147
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $12.63
High Stock Price Forecast: $22.00
Low Stock Price Forecast: $5.00
Forecasted Upside/Downside: +141.9%
Consensus Rating: Hold
Rating Score (0-4): 2.18
Research Coverage: 11 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.89)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-95,570,000.00
Net Margins: -45.96%
Pretax Margin: -45.75%
Return on Equity: -36.37%
Return on Assets: -28.14%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.78
Quick Ratio: 4.56

Sales & Book Value

Annual Sales: $84.99 million
Price / Sales: 2.68
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.50 per share
Price / Book: 2.09

Miscellaneous

Outstanding Shares: 43,620,000
Free Float: 34,242,000
Market Cap: $227.70 million
Optionable: Not Optionable
Beta: 0.71

10 Best Stocks to Own in 2023

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Thomas Gad (Age 53)
Founder, Interim CEO, Pres, Head of Bus. Devel. & Strategy and Director
Comp: $1.05M

Mr. Bo Kruse (Age 51)
Exec. VP, Sec., Treasurer & CFO
Comp: $685.02k

Ms. Susan Smith (Age 52)
Sr. VP & Chief Commercial Officer
Comp: $710k

Mr. Joris Wiel Jan Wilms (Age 49)
Sr. VP & COO

Dr. Torben Lund-Hansen M.Sc. (Age 72)
Ph.D., Sr. VP & CTO

Dr. Steen Lisby M.D. (Age 59)
M.Sc., Sr. VP & Chief Scientific Officer

Dr. Vignesh Rajah M.B.A. (Age 58)
MBBS, Sr. VP & Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

YMAB Stock - Frequently Asked Questions

Should I buy or sell Y-mAbs Therapeutics stock right now?: 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Y-mAbs Therapeutics in the last twelve months. There are currently 2 sell ratings, 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" YMAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in YMAB, but not buy additional shares or sell existing shares.
View YMAB analyst ratings or view top-rated stocks.
What is Y-mAbs Therapeutics' stock price forecast for 2023?: 11 Wall Street research analysts have issued 12 month price targets for Y-mAbs Therapeutics' shares. Their YMAB share price forecasts range from $5.00 to $22.00. On average, they expect the company's stock price to reach $12.63 in the next twelve months. This suggests a possible upside of 141.9% from the stock's current price.
View analysts price targets for YMAB or view top-rated stocks among Wall Street analysts.
How have YMAB shares performed in 2023?: Y-mAbs Therapeutics' stock was trading at $4.88 at the start of the year. Since then, YMAB shares have increased by 7.0% and is now trading at $5.22.
View the best growth stocks for 2023 here.
When is Y-mAbs Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our YMAB earnings forecast.
How were Y-mAbs Therapeutics' earnings last quarter?: Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) posted its quarterly earnings data on Thursday, August, 10th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.10. The firm earned $20.75 million during the quarter, compared to analyst estimates of $19.04 million. Y-mAbs Therapeutics had a negative net margin of 45.96% and a negative trailing twelve-month return on equity of 36.37%.
What guidance has Y-mAbs Therapeutics issued on next quarter's earnings?: Y-mAbs Therapeutics issued an update on its FY 2023 earnings guidance on Thursday, August, 10th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $80.00 million-$85.00 million, compared to the consensus revenue estimate of $82.79 million.
What other stocks do shareholders of Y-mAbs Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Y-mAbs Therapeutics investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Corbus Pharmaceuticals (CRBP), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV), Occidental Petroleum (OXY), VBI Vaccines (VBIV), Vaxart (VXRT) and Amarin (AMRN).

When did Y-mAbs Therapeutics IPO?: (YMAB) raised $80 million in an initial public offering on Friday, September 21st 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity acted as the underwriters for the IPO and BTIG was co-manager.
What is Y-mAbs Therapeutics' stock symbol?: Y-mAbs Therapeutics trades on the NASDAQ under the ticker symbol "YMAB."
Who are Y-mAbs Therapeutics' major shareholders?: Y-mAbs Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.80%), Polar Capital Holdings Plc (4.82%), State Street Corp (1.71%), Geode Capital Management LLC (1.63%), Acadian Asset Management LLC (1.50%) and Nuveen Asset Management LLC (0.97%). Insiders that own company stock include Biotech Aps Wg, Bo Kruse, David N Gill, Johan Wedell-Wedellsborg, Pedro Claus Juan Moller-San, Thomas Gad and Vignesh Rajah.
View institutional ownership trends.
How do I buy shares of Y-mAbs Therapeutics?: Shares of YMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Y-mAbs Therapeutics' stock price today?: One share of YMAB stock can currently be purchased for approximately $5.22.
How much money does Y-mAbs Therapeutics make?: Y-mAbs Therapeutics (NASDAQ:YMAB) has a market capitalization of $227.70 million and generates $84.99 million in revenue each year. The company earns $-95,570,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis.
How many employees does Y-mAbs Therapeutics have?: The company employs 147 workers across the globe.
How can I contact Y-mAbs Therapeutics?: Y-mAbs Therapeutics' mailing address is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. The official website for the company is www.ymabs.com. The company can be reached via phone at (646) 885-8505 or via email at info@ymabs.com.

This page (NASDAQ:YMAB) was last updated on 9/25/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial